alexa Journal of Inflammatory Bowel Diseases and Disorder: A New Paradigm Platform from Bench to Bedside | Open Access Journals
ISSN: 2476-1958
Journal of Inflammatory Bowel Diseases & Disorders
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Journal of Inflammatory Bowel Diseases and Disorder: A New Paradigm Platform from Bench to Bedside

Vuanghao L*

Integrative Medicine Cluster, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Penang, Malaysia

*Corresponding Author:
Vuanghao L
Integrative Medicine Cluster
Advanced Medical and Dental Institute
Universiti Sains Malaysia, Bertam 13200 Kepala Batas, Penang, Malaysia
Tel: 6045622427
E-mail: [email protected]

Received date: September 29, 2015; Accepted date: September 30, 2015 Published date: October 05, 2015

Citation: Vuanghao L (2015) Journal of Inflammatory Bowel Diseases and Disorder: A New Paradigm Platform from Bench to Bedside. J Inflam Bowel Dis Disor 1:e101. doi:10.4172/JIBDD.1000e101

Copyright: © 2015 Vuanghao L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Inflammatory Bowel Diseases & Disorders


Inflammatory colitis, Crohn’s disease (CD), and ulcerative colitis (UC) are classified under inflammatory bowel disease (IBD), which is a complex group of inflammatory conditions [1], wherein patients require both induction and lifelong medication [2.] The interaction between genetic factors and the environment causes IBD, and inflammatory gut diseases can be caused by modifications to enteral bacteria [3].

Few drugs have been approved by the FDA for the treatment of IBD, for example, budesonide, mesalamine, ciprofloxacin, certolizumab pegol, vedolizumab, and golimumab are used against the epidemiology of IBD. In addition to the approved drugs, many drugs are currently in Phase III trials, such as abatacept, adacolumn, adalimumab, infliximab, and azathioprine [4]. The use of immune-suppressants, corticosteroids, and antitumor necrosis factor for IBD treatment has been widely known [2]. Consequently, the following question has been posed: why do these treatments cause risks of infection and cancerous growth? Therefore, researchers have started to study the use of complementary and alternative medicine (CAM) because patients with IBD claim that CAMs are safer and less toxic than conventional treatment. The survey revealed that approximately half of the patients (mostly adults and children) with IBD used CAM for their treatment [5,6].

The use of herbs for IBD treatment is increasing worldwide. Herbs such as bilberry [7] and Jian Pi Ling [8] showed effectiveness when administered in patients with UC. Artemisia absinthium and mastic gum also showed promising results on CD [9,10]. CAM treatment for IBD is continuously increasing and may become a new effective and less expensive treatment method in the future. Considering that CAM has gained popularity in IBD treatment, a number of questions arise: given that the results obtained from in vitro studies are not equally effective in vivo, what is the efficacy of herbal preparation for IBD patients and what is the duration of the long-term safety of herbal treatment?

Most clinical studies on drugs for IBD (anti-UC and anti-CD) present unsatisfactory results. Nevertheless, the information obtained from published studies show useful information, particularly on the early diagnosis of IBD development and on the improvement of clinical trials. Clinical studies were not only conducted on synthetic drugs but also on herbal therapy for IBD. Although data have shown the promising effectiveness of herbal therapy, some studies lack conclusive results and employ a huge number of patients to achieve a positive risk–benefit ratio in IBD. Given this situation, more attention should be paid to the etiology and pathophysiology of IBD to provide optimal clinical trial data. Finally, before we close the chapter on IBD, further research needs to be performed from the bench to the bedside. Thus, we invite researchers to provide the results of their studies, as well as their valuable comments and views, on drug discovery, drug mechanisms, CAM, IBD-targeted drug delivery, and clinical trials in this journal.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 8347
  • [From(publication date):
    June-2016 - Oct 22, 2017]
  • Breakdown by view type
  • HTML page views : 8258
  • PDF downloads :89

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version